Category: Start-ups

Phitonex, Inc. is bringing a new way of thinking about fluorescence and experimental design to the life science laboratory. We will transform the way light is used in life science with a first focus on single cells, the fundamental unit of health and disease.

We have developed a platform that allows us to deterministically engineer optical properties to provide high resolution analysis of single cells by flow cytometry, and in the future, other applications. Lower noise, less spectral overlap, and fluorescence-by-design means that our dyes immediately unlock a higher number of parameters across current instrumentation and provide unmatched cell population resolution to drive enhanced biological insight.

We are also the first team to develop, design, and validate spectral dyes.

Gastroenterologists are some of the busiest specialists in the hospital. There is an expected shortage of gastroenterologists by 2024, of about 10%. Endoscopy represents approximately 70% of our daily activities.

Verity BioSciences is hoping to replace or reinforce the post op conversation with individalized videos.

HOMOLOGY-INDEPENDENT UNIVERSAL GENOME ENGINEERING -HIUGE-

HiUGE is a CRISPR-based solution for easy labeling of your endogenous proteins in cells or tissue. Traditional antibody approaches developed in the 1970s to study proteins are plagued by non-specific binding to other proteins, lot-to-lot variability, and are difficult to experimentally validate. In contrast, labeling with HiUGE enables researchers the ability to visualize and study their proteins of interest with the high degree of specificity and reproducibility afforded by modern molecular biology.

Our products consists of two Adeno-associated viruses: a gene-specific gRNA virus that directs the cutting of your gene at the N- or C-terminus coding region of your protein; and a payload virus that delivers epitope tags, fluorescent proteins, or premature stop codons to be incorporated into your protein.

Highlights

• Novel CRISPR gene editing technology to allow functional studies of proteins.

• Enables consistent detection of any protein of interest in cells or tissue, regardless of species.

• Powerful solution for researchers that have no validated reagents developed for their targets.

• Validated in vitro in mouse and human.

• Validated in vivo in tissue.

• Peer-reviewed publication in Neuron.

Helminths as therapeutics to improve human health

Developed by DCRI, the platform involves videos and electronic means of consenting patients in a clinical trial.

Sisu Pharma is dedicated to developing targeted drugs for patients with therapy-resistant Prostate Cancer. Prostate Cancer is the second most common cancer in men worldwide and there were over 1.3 million new cases of the disease globally in 2018. There are several treatments available for Prostate Cancer but none are curative and prolonged treatment inevitably results in resistance and death. Sisu Pharma’s proprietary technology specifically targets a key protein that is critical to the survival and spread of advanced Prostate Cancer, providing desperately needed treatment for patients with no remaining options.